Oropharynx Cancer clinical trials at UCSF
3 in progress, 0 open to eligible people
Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
Sorry, in progress, not accepting new patients
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
San Francisco, California and other locations
Cemiplimab ± ISA101b in HPV16-Positive OPC
Sorry, in progress, not accepting new patients
This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.
San Francisco, California and other locations
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Sorry, in progress, not accepting new patients
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet known how much extra treatment needs to be given after surgery.
San Francisco, California and other locations
Our lead scientists for Oropharynx Cancer research studies include Alain Algazi.
Last updated: